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Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative 
disease in which motor neurons in the brain and spinal 
cord degenerate, resulting in progressive paralysis 
ultimately leading to dependence on mechanical 
ventilatory support or death, usually within 3 years. 
Riluzole, a benzothiazole derivative, improves survival in 
patients with ALS;1 however, the eﬀ ect is moderate 
and there remains a pressing need for more eﬀ ective 
disease-modifying treatments. 
Lithium has neuroprotective eﬀ ects in cell2–6 and 
animal7 models of neurodegeneration, including ALS, 
although not in all studies.8,9 In a positive study, 
transgenic ALS mice treated with lithium showed 
improved survival compared with wild-type mice treated 
with saline,7 and in a pilot study of lithium in patients 
with ALS there was a signiﬁ cant eﬀ ect on survival in the 
lithium plus riluzole group compared with the riluzole 
only group.7 The design of that trial could be criticised 
because the method of randomisation was not stated, it 
was not placebo-controlled, and only 44 patients were 
included.7,10 However, the reported diﬀ erence in survival 
at 15 months (100% survival in the lithium plus riluzole 
group compared with 70% in the riluzole only group),7 
taken together with the neuroprotective and 
neuroregenerative eﬀ ects of lithium in the cell and 
animal models, suggested that a deﬁ nitive randomised 
placebo-controlled trial was warranted. Therefore, a UK 
group of Motor Neurone Disease Association-supported 
ALS centres within the Dementias and Neurodegenerative 
Diseases Research Network (DeNDRoN) designed and 
undertook the lithium carbonate in amyotrophic lateral 
sclerosis (LiCALS) trial to test the hypothesis that lithium 
improves survival in ALS. Although several other trials 
were either in progress at the time or were planned, we 
knew that none had the same survival-based design, and 
we argued that a deﬁ nitive answer was needed to show 
whether lithium has a biologically and clinically 
signiﬁ cant eﬀ ect on survival and function and is safe and 
well tolerated in ALS.
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Summary
Background Lithium has neuroprotective eﬀ ects in cell and animal models of amyotrophic lateral sclerosis (ALS), and 
a small pilot study in patients with ALS showed a signiﬁ cant eﬀ ect of lithium on survival. We aimed to assess whether 
lithium improves survival in patients with ALS.
Methods The lithium carbonate in amyotrophic lateral sclerosis (LiCALS) trial is a randomised, double-blind, placebo-
controlled trial of oral lithium taken daily for 18 months in patients with ALS. Patients aged at least 18 years who had 
ALS according to the revised El Escorial criteria, had disease duration between 6 and 36 months, and were taking 
riluzole were recruited from ten centres in the UK. Patients were randomly assigned (1:1) to receive either lithium or 
matched placebo tablets. Randomisation was via an online system done at the level of the individual by block 
randomisation with randomly varying block sizes, stratiﬁ ed by study centre and site of disease onset (limb or bulbar). 
All patients and assessing study personnel were masked to treatment assignment. The primary endpoint was the rate 
of survival at 18 months and was analysed by intention to treat. This study is registered with Eudract, number 
2008-006891-31.
Findings Between May 26, 2009, and Nov 10, 2011, 243 patients were screened, 214 of whom were randomly assigned 
to receive lithium (107 patients) or placebo (107 patients). Two patients discontinued treatment and one died before 
the target therapeutic lithium concentration could be achieved. 63 (59%) of 107 patients in the placebo group and 
54 (50%) of 107 patients in the lithium group were alive at 18 months. The survival functions did not diﬀ er signiﬁ cantly 
between groups (Mantel-Cox log-rank χ² on 1 df=1·64; p=0·20). After adjusting for study centre and site of onset 
using logistic regression, the relative odds of survival at 18 months (lithium vs placebo) was 0·71 (95% CI 0·40–1·24). 
56 patients in the placebo group and 61 in the lithium group had at least one serious adverse event.
Interpretation We found no evidence of beneﬁ t of lithium on survival in patients with ALS, but nor were there safety 
concerns, which had been identiﬁ ed in previous studies with less conventional designs. This ﬁ nding emphasises the 
importance of pursuing adequately powered trials with clear endpoints when testing new treatments.
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Methods
Patients
LiCALS was a multicentre, double-blind, randomised, 
placebo-controlled trial undertaken at specialist ALS 
clinics at ten participating centres in the UK. The full 
protocol is described elsewhere.11 Eligible participants 
were adults aged at least 18 years who met the following 
criteria: possible, laboratory supported probable, probable, 
or deﬁ nite ALS according to the revised version of the 
El Escorial criteria (the Airlie House Statement);12 an 
electromyogram compatible with ALS; disease duration of 
at least 6 months and no more than 36 months (inclusive); 
and receipt of riluzole treatment for at least 1 month 
before enrolment. Women of childbearing potential were 
excluded if pregnant, if breastfeeding, or if a urine 
pregnancy test before randomisation was not negative. 
Exclusion criteria included participation in another 
therapeutic study in the preceding 12 weeks, use of other 
investigational drugs, tracheostomy or other assisted 
ventilation in the preceding 3 months, an existing 
gastrostomy, a medical disorder that might interfere with 
diagnosis or functional assessment, hepatic or renal 
insuﬃ  ciency, a major psychiatric disorder, clinically 
evident dementia, or allergy to lithium.
All participants gave written, informed consent to 
participate before screening. The study was ethically 
approved by the South East Research Ethics Committee, 
reference 09/H1102/15.
Randomisation and masking
Randomisation was done via an online system based at 
the King’s Clinical Trials Unit (CTU) at the Institute of 
Psychiatry (London, UK). Patients were randomised (1:1) 
to lithium or placebo at the level of the individual by block 
randomisation with randomly varying block sizes, 
stratiﬁ ed by study centre and site of disease onset (limb or 
bulbar). Active and placebo lithium tablets were identical 
in appearance, dimensions, mass, and disintegration 
time, and patients were prescribed up to three tablets 
daily, adjusted according to serum lithium concentrations. 
Active tablets contained 295 mg of lithium. The aim was 
to achieve therapeutic lithium concentrations, deﬁ ned as 
0·4–0·8 mmol/L. To maintain double-blind status while 
retaining the ability to monitor lithium concentrations, 
one physician from each site was unmasked but had no 
patient contact. The unmasked physician instructed the 
masked physicians and nurses to adjust the dose. 
Unmasked research nurses assisted unmasked physicians 
in the collection of laboratory results and in ensuring sign 
oﬀ  by the physician administering lithium. Blood lithium 
concentrations were entered on a web-based electronic 
case report form system, which was accessible only to the 
study data manager and the unmasked physicians so that 
central monitoring of lithium concentrations was possible. 
The unmasked physician adjusted the lithium dose of 
patients in response to lithium concentrations and the 
King’s CTU checked that this process was consistent and 
timely. For patients on placebo, sham dose adjustments 
were recommended to the unmasked physician by the 
CTU to avoid unmasking. Placebo dose adjustments were 
done by pairing patients in the lithium and placebo groups 
as they were randomised. Each time a patient in the 
lithium group was randomly assigned a group, the 
unmasked study data manager was alerted by the 
randomisation system when the next patient in any centre 
was randomly assigned to placebo. The data manager 
then monitored the dose adjustments of the patient in the 
lithium group who was randomised ﬁ rst and instructed 
the study physician of the paired patient on placebo to 
adjust the dose of study drug at the same time after 
randomisation as for the active patient and to the same 
dose adjustment. This process was monitored to ensure 
masked physicians and nurses remained masked 
throughout the trial (appendix). Adverse events were 
managed by clinicians masked to treatment allocation and 
serum lithium concentrations. 
Procedures
The primary outcome was death from any cause at 
18 months, deﬁ ned from date of randomisation and 
veriﬁ ed with documented evidence of death or of survival 
beyond 18 months in all cases. Secondary outcome 
measures, which comprised functional health status 
measured with the ALS functional rating scale-revised 
(ALSFRS-R), mental health state measured with the 
hospital anxiety and depression scale, and quality of life 
measured with the EuroQol (the EuroQoL group 
5-dimension self-report questionnaire health state tariﬀ  
and health evaluation scale), were assessed at baseline and 
3, 6, 9, 12, 15, and 18 months. Reports of adverse events, 
whether related to the study drug or not, were collected 
and recorded at each timepoint. The masked physician at 
each site was responsible for deciding whether an adverse 
event was serious according to the Good Clinical Practice 
guidelines. Completed serious adverse event forms were 
then sent to the coordinating centre for review by the 
Chief Investigator. Non-serious adverse events were 
recorded in the electronic case report form alone.
Statistical analysis
The sample size was based on detection of a diﬀ erence in 
survival rates at 18 months using Fleiss’s method for a 
proportion incorporating a continuity correction. Two 
groups of 110 patients would give 80% power to detect a 
diﬀ erence of 17·5% in survival rates (65% vs 82·5%) 
assuming a two-sided type 1 error rate of 5%. The ﬁ gure 
of 82·5% represents a treatment eﬀ ect midway between 
a typical survival rate at 18 months of 65% and the 100% 
survival reported in the original positive lithium study.7 
The primary analysis was of survival rates at 18 months 
in patients randomised to lithium treatment versus 
patients randomised to placebo by intention to treat, 
compared by the Mantel-Cox log-rank χ² statistic. 
Originally, a test of survival proportions was planned, but 
See Online for appendix
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clinical feedback suggested that survival over the entire 
study was important, and a log-rank test would be more 
in keeping with other studies of other drugs for treatment 
of ALS. This decision was made in August, 2010, before 
the masking was broken. This endpoint was a protocol 
amendment that was approved by the trial steering 
committee before the protocol was published (September 
2011). Two further pre-speciﬁ ed analyses of the primary 
outcome measure were done: an intention-to-treat 
analysis of survival rates at 18 months using logistic 
regression with adjustment for randomisation strata, 
and a per-protocol analysis of time to death (censored at 
18 months) using a Cox proportional hazards model. 
Patients were included in these analyses only if they had 
taken at least 75% of tablets prescribed in every quarter 
during participation. 
Compliance was assessed using the number of tablets 
prescribed as recorded in the medication log compared 
with the number of tablets returned to the pharmacy at 
each study visit. The site nurses recorded the returns in 
the electronic case report form, site pharmacies recorded 
the returns independently in the pharmacy ﬁ le, and the 
trial manager checked discrepancies between electronic 
case report form and pharmacy ﬁ les during site visits, to 
ensure the correct returns were recorded on both, before 
drug returns were shipped back to the manufacturer for 
eventual destruction. 
Rate of change in each of the secondary outcome 
measures was compared between groups using mixed 
models with variation between patients and variation 
between occasions nested within patients treated as 
random eﬀ ects. Time in years was treated as a continuous 
variable. Results, adjusted for diﬀ erences between 
randomisation strata, are given in the form of diﬀ erences 
in rate of change with corresponding 95% CIs between 
patients assigned to lithium and those assigned to placebo. 
This approach was extended to assess the eﬀ ect of missing 
data13 by joint modelling of the survival data (with a Cox 
proportional hazards model) and the secondary outcomes 
(with mixed models similar to those described earlier). The 
Cox model was built by forward stepwise regression, but 
backward elimination gave the same model. The variables 
included were El Escorial category, age of onset, slow vital 
capacity, and sex. An eﬀ ect of lithium was then added to 
the model. Variables excluded were handedness, site of 
symptom onset, time between onset and diagnosis, and 
pulse rate. Within both of these models, an additional 
latent variable was included that can be conceptualised as 
the propensity to experience poor outcomes. The inclusion 
of this latent variable is common to both models and 
allows us to adjust our estimates of the treatment eﬀ ect to 
allow for the diﬀ erent rates of dropout in each group. Both 
models were estimated simultaneously, thus maximising 
the joint likelihood over both the survival and repeated 
measures data. Results are given in the form of the 
diﬀ erence in rate of change of each of the secondary 
outcomes with corresponding 95% CIs.
Time to ﬁ rst serious adverse event was analysed with a 
Cox proportional hazards model. We calculated hazard 
ratios (risk of a serious adverse event) and associated 
95% CIs for patients assigned to lithium compared with 
patients assigned to placebo for all serious adverse events 
and for all serious adverse events excluding death. For 
quality of life scores, data imputation was undertaken 
provided at least half of the items in any scale had been 
completed; the imputed missing value was deﬁ ned as the 
mean value of the non-missing items.
This study is registered with Eudract, number 
2008-006891-31.
Role of the funding source
The funding source had no role in study design, data 
collection, data analysis, data interpretation, writing of the 
report, or the decision to submit for publication. The 
corresponding author had full access to all data in the 
study, and the manuscript was written by the corresponding 
author with assistance from other members of the writing 
committee. The corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
The ﬁ gure shows the trial proﬁ le. Between May 26, 2009, 
and Nov 10, 2011, 243 patients were screened, 214 of whom 
were recruited from ten centres (appendix) and were 
randomly assigned to lithium (n=107) or to placebo 
(n=107). The groups were well balanced for demographic 
and clinical characteristics at baseline (table 1). Compliance 
was good, with 140 patients (65%) taking at least 75% of the 
prescribed drug in every quarter. Compliance was better in 
the placebo group (71%) than in the lithium group (60%). 
During the course of the study, 65 patients withdrew from 
Figure: Trial proﬁ le
107 assigned to lithium 107 assigned to placebo
3 excluded
    2 withdrew
    1 died
107 included in intention-to-treat analysis 107 included in intention-to-treat analysis
243 assessed for eligibility
29 ineligible
       4 did not meet diagnostic criteria
       7 had slow vital capacity <60% of predicted
       2 had existing gastrostomy
        9 had hepatic or renal insuﬃciency
       3 had contraindications to lithium 
       2 were unable to provide informed consent
       2 refused to participate
214 randomised
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the study drug (23 on placebo and 42 on lithium), 41 owing 
to adverse events (12 on placebo and 29 on lithium), seven 
because they were no longer able to travel to the centre 
(three on placebo and four on lithium), and 17 for other 
reasons (eight on placebo and nine on lithium).
Of 107 patients randomly assigned to treatment with 
lithium carbonate, 104 (97%) had at least one blood 
lithium concentration measurement in the therapeutic 
range (0·4–0·8 mmol/L), with the mean number of such 
measurements being 6·6 (SD 2·9; appendix). Of the 
three patients who did not achieve the therapeutic range, 
one withdrew after becoming pregnant, one withdrew 
after an adverse event 1 week into the study, and one had 
a serious adverse event leading to death before the 
therapeutic range could be achieved.
Other factors that potentially inﬂ uenced survival did 
not diﬀ er signiﬁ cantly between groups. By the end of the 
18 month follow-up period or at time of death, 36 (34%) 
patients in the placebo group and 25 (23%) in the lithium 
group had received percutaneous endoscopic gastrostomy 
(relative risk 0·69, 95% CI 0·45–1·07). 29 (27%) patients 
in the placebo group and 27 (25%) in the lithium group 
had received non-invasive ventilation (relative risk 0·93, 
95% CI 0·59–1·46).
63 (59%) patients in the placebo group (56 on study drug 
and seven oﬀ  study drug) and 54 (50%) patients in the 
lithium group (41 on study drug and 13 oﬀ  study drug) 
were alive at 18 months. The survival functions did not 
diﬀ er signiﬁ cantly between groups (Mantel-Cox log-rank 
χ² statistic on 1 df=1·64; p=0·20). In a post-hoc analysis, 
after adjusting for study centre and site of onset using a 
Cox proportional hazards model, the estimated hazard 
ratio (lithium vs placebo) was 1·35 (95% CI 0·90–2·02). 
The corresponding result in patients who complied with 
their treatment (64 in the lithium group and 76 in the 
placebo group)  was 1·40 (95% CI 0·83–2·34). The relative 
odds of survival at 18 months (lithium vs placebo) adjusted 
for centre and site of onset was 0·71 (95% CI 0·40–1·24). 
Therefore, there was no evidence that treatment with 
lithium inﬂ uenced survival in this patient population.
Table 2 lists the mean scores for the secondary outcome 
measures. The analytical strategy was to compare the rate 
of change of health status in the two groups by ﬁ tting 
statistical models that allowed for repeated measures 
within individuals, for diﬀ erences between randomisation 
strata, and for loss to follow-up (appendix). There was a 
marked deterioration in functional health status in both 
treatment groups. 
In the unadjusted analysis for the ALSFRS-R—a 
functional scale from 0 to 48, where 48 is maximal 
function—the annual rate of change was –9·31 (95% CI 
–10·5 to –8·58) in the placebo group and –9·50 
(–10·31 to –8·70) in the lithium group (appendix). The 
diﬀ erence between these rates was –0·19 (–1·28 to 0·90) 
and was not signiﬁ cant. Based on joint modelling, the 
rate of change in ALSFRS-R adjusted for survival was 
–9·47 (95% CI –10·98 to –8·46) in the placebo group and 
–9·75 (–11·62 to –8·47) in the lithium group. These 
increases in the estimated magnitude of change are 
consistent with the assumption that those patients who 
were lost to follow-up were those with the poorest 
functional status. As in the unadjusted analysis, the 
diﬀ erence between these rates of decline in this adjusted 
analysis was not statistically signiﬁ cant (diﬀ erence –0·28, 
95% CI –2·40 to 1·67), and this remained non-signiﬁ cant 
after adjustment for strata (appendix).
Anxiety scores increased over the period of the study 
but the increases were small and the diﬀ erence between 
groups was not signiﬁ cant (appendix). Patients in both 
groups became more depressed over time, but the 
diﬀ erence in the rate of change was not signiﬁ cant 
(estimated diﬀ erence based on the joint model adjusting 
for randomisation strata was 0·29, 95% CI 0·33 to 1·02). 
Similarly, quality of life deteriorated over time in both 
groups but the diﬀ erence in the rate of change was not 
signiﬁ cant.
117 patients had at least one serious adverse event 
during the 18 month follow-up period (56 patients in the 
placebo group and 61 patients in the lithium group; 
table 3). Four patients had three recorded serious adverse 
events, 30 patients had two, and 83 patients had one. 
The estimated hazard ratios (lithium vs placebo) were 
1·14 (95% CI 0·79–1·65) for all serious adverse events 
Placebo (n=107) Lithium (n=107)
Women 30 (28%) 36 (34%)
Ethnic origin, white 104 (97%) 106 (99%)
Age at recruitment (years) 59·5 (11·5) 59·7 (9·9)
Time from onset of symptoms to diagnosis (weeks) 47·0 (27·8) 46·3 (26·3)
Time from diagnosis to recruitment (weeks) 36·8 (29·0) 34·0 (28·1)
Disease duration at start of study (weeks) 80·3 (33·8) 83·8 (36·0)
Bulbar site of onset 24 (22%) 23 (22%)
Sporadic type of onset 83 (78%) 84 (79%)
Right handedness 94 (88%) 92 (86%)
El Escorial diagnostic category
Clinically deﬁ nite ALS 41 (38%) 41 (38%)
Clinically probable ALS 43 (40%) 37 (35%)
Clinically probable laboratory supported ALS 18 (17%) 20 (19%)
Clinically possible ALS 5 (5%) 9 (8%)
Vital capacity in spirometry (% predicted) 89·3 (17·0) 93·3 (18·5)
Pulse rate (beats per min) 74·4 (12·2) 76·7 (13·9)
Systolic blood pressure (mm Hg) 135·0 (16·9) 132·6 (15·8)
Diastolic blood pressure (mm Hg) 84·1 (12·0) 83·6 (15·3)
Time on riluzole at entry to study (days) 198·5 (177·7) 209·6 (192·0)
ALS functional rating scale-revised 38·64 (5·72) 38·20 (5·66)
HADS anxiety 4·46 (3·76) 4·59 (3·37)
HADS depression 4·00 (3·10) 3·89 (2·84)
EuroQoL health state tariﬀ 0·59 (0·28) 0·59 (0·30)
EuroQol health evaluation 70·07 (19·48) 68·50 (18·50)
Data are number (%) or mean (SD). ALS=amyotrophic lateral sclerosis. HADS=hospital anxiety and depression scale. 
Table 1: Demographic and baseline characteristics
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and 0·84 (0·52–1·36) for events excluding death, neither 
of which were signiﬁ cant.
Discussion 
In this double-blind, randomised controlled trial of 
lithium versus placebo in ALS using a survival design, 
we found that there was no evidence that treatment with 
lithium resulted in an increase in survival at 18 months 
(panel). There was a marked deterioration in functional 
health status and quality of life, with an associated 
increase in depression and anxiety over time in patients 
assigned to either treatment group. 
The ﬁ rst reported study of lithium in patients with ALS7 
examined 44 patients, 16 given lithium and riluzole and 
28 given riluzole alone. There were no deaths at 15 months 
in the riluzole and lithium group compared with eight 
(29%) in the riluzole only group. Furthermore, patients in 
the lithium group showed little progression on functional 
measures compared with typical progression in the 
control group. This study came after a study of mutant 
SOD1 transgenic mice that showed compelling evidence 
for a neuroprotective eﬀ ect of lithium in ALS.7 The study 
was not placebo controlled and was small, although 
adequately powered to detect an eﬀ ect similar to that 
noted in the mice.7 Our study was powered to detect an 
eﬀ ect on survival but, additionally, neither standard 
analysis of function nor joint analysis of function and 
survival, which accounts for the loss of those dying with 
worse function, showed any beneﬁ t of lithium.
Similar ﬁ ndings have been noted in other studies 
(table 4), although none of these had the traditional design 
of the present study, in which survival was used as an 
endpoint in a ﬁ xed-duration study with two treatment 
groups. Thus, despite several studies that failed to show 
evidence of beneﬁ t for lithium therapy in ALS, none was a 
traditionally designed double-blind, placebo-controlled, 
randomised trial with a primary endpoint of survival, and 
arguably none of these trials could robustly resolve whether 
0 months 3 months 6 months 9 months 12 months 15 months 18 months
ALS functional rating scale-revised
Placebo 38·64 (5·72) 35·27 (8·09) 33·43 (8·74) 32·13 (8·42) 30·20 (8·90) 28·88 (9·14) 28·54 (9·27)
Lithium 38·20 (5·66) 36·17 (6·65) 32·40 (8·24) 30·04 (8·55) 28·31 (9·50) 29·47 (10·23) 29·32 (9·96)
HADS anxiety*
Placebo 4·46 (3·76) 4·33 (3·62) 4·19 (3·76) 4·53 (3·86) 4·67 (4·05) 4·54 (4·03) 3·50 (3·54)
Lithium 4·59 (3·37) 5·03 (4·19) 5·30 (4·08) 5·09 (3·90) 5·96 (4·42) 5·26 (4·05) 4·55 (4·26)
HADS depression*
Placebo 4·00 (3·10) 4·36 (3·06) 4·53 (3·65) 4·74 (3·30) 5·05 (3·62) 5·67 (3·96) 4·71 (3·76)
Lithium 3·89 (2·84) 4·83 (3·32) 5·61 (3·66) 5·80 (3·45) 5·88 (3·60) 5·03 (3·60) 5·17 (3·92)
EuroQoL health state tariﬀ 
Placebo 0·59 (0·28) 0·50 (0·31) 0·46 (0·34) 0·42 (0·33) 0·37 (0·34) 0·33 (0·32) 0·33 (0·35)
Lithium 0·59 (0·30) 0·54 (0·35) 0·42 (0·38) 0·35 (0·35) 0·30 (0·38) 0·32 (0·39) 0·30 (0·40)
EuroQoL health evaluation 
Placebo 70·07 (19·48) 63·74 (22·32) 64·89 (20·21) 64·60 (21·31) 61·97 (21·36) 59·43 (21·74) 61·95 (23·97)
Lithium 68·50 (18·50) 64·09 (22·22) 61·17 (21·37) 60·14 (21·11) 57·03 (24·48) 56·40 (24·07) 56·36 (22·86)
Data are mean (SD). ALS=amyotrophic lateral sclerosis. HADS=hospital anxiety and depression scale. *For the two HADS scales, a higher score corresponds to poorer 
outcome; for all other outcomes a higher score corresponds to better outcome.
Table 2: Secondary outcome measures, by time since randomisation
Placebo Lithium Total
None 51 46 97
1 event 41 42 83
2 events 14 16 30
3 events 1 3 4
Total 107 107 214
Data are number of patients. One patient had a serious adverse event between 
two screening visits and before signing the consent form. Because this event 
occurred before randomisation it has been excluded from the analysis. The 
relative risk of a serious adverse event (including death) in the lithium group 
compared with the placebo group was 1·09 (95% CI 0·58–1·39).
Table 3: Serious adverse events
Panel: Research in context
Systematic review
We searched PubMed for reports published before Dec 1, 2012, using the following terms: 
“lithium” and “amyotrophic lateral sclerosis”, “motor neuron disease”, “motor neurone 
disease”, “ALS”, or “MND”. We included randomised, placebo-controlled trials and trials of 
other designs in amyotrophic lateral sclerosis (ALS) or a related disorder that involved 
lithium. We identiﬁ ed six previous trials, three of which were randomised, placebo-controlled 
trials,14–16 one that was randomised but not placebo controlled,7 one that used historical 
controls,17 and one that used self-reporting by patients.18 We noted that all six trials used 
diﬀ erent, non-traditional methods for design or analysis or both. We did a randomised, 
double-blind, placebo-controlled trial with a primary endpoint of survival rates at 18 months 
in 214 patients with ALS, half assigned to lithium treatment and half assigned to placebo.
Interpretation
We noted no diﬀ erence in survival between placebo and lithium groups. This study 
conﬁ rms the absence of beneﬁ t of lithium for treatment of ALS.
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lithium could have a small but biologically signiﬁ cant 
eﬀ ect on ALS progression, as measured by the gold 
standard endpoint for phase 3 studies, survival. Although 
our study is underpowered for detection of a small change 
in survival (eg, 5–10%, as detected for riluzole1), we 
accepted this limitation as a pragmatic compromise for an 
academic-led trial with limited ﬁ nancial resources and 
without the need for regulatory approval had we detected a 
beneﬁ cial eﬀ ect. Adjusting for study centre and site of 
onset, the relative odds of survival at 18 months (lithium vs 
placebo) was 0·71 (95% CI 0·40–1·24). Our projected 
survival rates of 65% and 82·5% in an achieved sample of 
214 patients would correspond to an odds ratio of 2·54—
signiﬁ cantly higher than the upper limit of 1·24 in our 
estimate. We can therefore be conﬁ dent that if there is any 
eﬀ ect of treatment with lithium on survival, it is very much 
lower than that hypothesised. 
Studies of function in clinical trials of ALS are diﬃ  cult 
because patients with the worst function are most likely 
to die and no longer contribute scores to the mean; any 
decline is masked and there is reduced power to detect an 
eﬀ ect. We have approached this problem in two ways. 
First, we analysed the outcomes in patients who did not 
survive until the study end, conﬁ rming outcomes were 
indeed poorer. Second, we adjusted for loss to follow-up, 
conﬁ rming that this adjustment increases the estimated 
annual change in functional scores, mental health scores, 
and quality of life. By undertaking a joint analysis of 
survival and function, we were able to control for the loss 
to follow-up in the comparison between treatment groups 
and showed no beneﬁ t of treatment. Further studies are 
needed to identify the optimum method for analysis of 
functional scores in trials of treatments in ALS. 
In this phase 3, randomised, placebo-controlled, 
double-blind trial of lithium therapy in ALS, we did not 
ﬁ nd evidence of beneﬁ t, but nor were there safety 
concerns, which had been identiﬁ ed in previous studies 
with less conventional designs.14 This ﬁ nding emphasises 
the importance of pursuing adequately powered trials 
with clear endpoints when testing new treatments, 
bearing in mind that a trial tests biologically important 
hypotheses as well as clinical eﬃ  cacy. Previous lithium 
trials could not adequately address this issue, but our 
results suggest that we can now be conﬁ dent that lithium 
at these serum concentrations does not signiﬁ cantly 
inﬂ uence disease progression, as assessed either by a 
validated functional measure (ALFRS-R) or by survival. 
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